DXC Technology (DXC) Could Be 20% Overvalued On Cut Full Year Guidance

DXC Technology (DXC) moved back into focus after fiscal Q2 2027 results came in soft, with management cutting full year revenue and adjusted EPS guidance following weaker bookings and slower pipeline conversion.

At a share price of US$14.98, DXC Technology has given investors a 30 day share price return of about 35% and a 90 day share price gain of roughly 37%, yet the 1 year total shareholder return is only 5.5% and the 5 year total shareholder return is down about 56%.

The sharp pullback around the Q2 report, including a 1 day share price decline of about 1.6% and a weaker 7 day share price move, suggests traders are reassessing execution risk after the guidance cut, even though the stock is still materially higher than it was a month ago.

Rumors about a possible US$2.4b sale of the insurance software and services arm and management’s push into AI offerings help explain why momentum had been building into late October, while the latest outlook reset has cooled some of that optimism and shifted attention back to the long running revenue pressures.

Spot under-pressure turnarounds like DXC Technology alongside other hand-picked IT and software plays by scanning our 19 high quality undiscovered gems for companies investors may not be fully pricing in.

DXC Technology has just surged on AI hopes and deal talk, then run into softer guidance and fresh execution questions. For anyone eyeing the turnaround story, the key question is whether patience for a better entry price is worth more than jumping in now.

Most Popular Narrative: 20% Overvalued

Against the narrative fair value of $12.50, DXC Technology at $14.98 screens as rich, with the story hinging on an AI and margin reset that still needs to play out in the real numbers.

The main thing that has to go right is DXC Technology executing on its shift from labor intensive services to AI driven, product and SaaS led offerings while delivering the planned $1.0 to $1.5 billion cost reduction and margin uplift.

The current valuation and this narrative’s view that DXC Technology is fairly valued and bullish together imply that the share price already reflects both the execution risks around the AI transition and the potential benefits from higher margin, capital light growth.

See why 14 investors see DXC Technology as 20% overvalued.

Result: Fair Value of $12.50 (OVERVALUED)

Still, DXC Technology faces two clear swing factors: ongoing organic revenue declines in areas like GIS, and the overhang from the securities fraud investigation.

Find out about the key risks to this DXC Technology narrative.

Another View: DXC Technology On Earnings Multiples

The narrative fair value paints DXC Technology as overvalued, yet on plain P/E math the picture looks softer. The stock trades at 20.8x earnings, below both peers at 22.5x and the US IT group at 22.4x, and under a fair ratio of 22.9x that the market could eventually lean toward.

That gap points to a tug of war between concerns over shrinking revenue and low returns on equity, and a price tag that is not stretched relative to sector and fair ratio benchmarks. Which story do you think deserves more weight when you look at DXC Technology today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around DXC Technology can make the story feel messy, yet that is exactly when fresh data matters most. If you want to evaluate the downside and the upside in a structured way, start with the 3 key rewards and 3 important warning signs.

Looking for more DXC Technology sized opportunities?

If DXC Technology has your attention, do not stop here. Broaden your watchlist with fresh ideas that match the kind of edge you want in your portfolio.

Scan targeted opportunities using the Simply Wall St Screener so you do not miss quality setups in corners of the market others might be ignoring.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DXC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]